Cargando…

Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options

Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Löscher, Wolfgang, Potschka, Heidrun, Sisodiya, Sanjay M., Vezzani, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300324/
https://www.ncbi.nlm.nih.gov/pubmed/32540959
http://dx.doi.org/10.1124/pr.120.019539
_version_ 1783547564982796288
author Löscher, Wolfgang
Potschka, Heidrun
Sisodiya, Sanjay M.
Vezzani, Annamaria
author_facet Löscher, Wolfgang
Potschka, Heidrun
Sisodiya, Sanjay M.
Vezzani, Annamaria
author_sort Löscher, Wolfgang
collection PubMed
description Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with such drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life, so development of more effective therapies is an urgent clinical need. However, the various types of epilepsy and seizures and the complex temporal patterns of refractoriness complicate the issue. Furthermore, the underlying mechanisms of DRE are not fully understood, though recent work has begun to shape our understanding more clearly. Experimental models of DRE offer opportunities to discover, characterize, and challenge putative mechanisms of drug resistance. Furthermore, such preclinical models are important in developing therapies that may overcome drug resistance. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of ASD resistance and discuss how to overcome this problem. Encouragingly, better elucidation of the pathophysiological mechanisms underpinning epilepsies and drug resistance by concerted preclinical and clinical efforts have recently enabled a revised approach to the development of more promising therapies, including numerous potential etiology-specific drugs (“precision medicine”) for severe pediatric (monogenetic) epilepsies and novel multitargeted ASDs for acquired partial epilepsies, suggesting that the long hoped-for breakthrough in therapy for as-yet ASD-resistant patients is a feasible goal. SIGNIFICANCE STATEMENT: Drug resistance provides a major challenge in epilepsy management. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of drug resistance in epilepsy and discuss how the problem might be overcome.
format Online
Article
Text
id pubmed-7300324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The American Society for Pharmacology and Experimental Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-73003242020-07-01 Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options Löscher, Wolfgang Potschka, Heidrun Sisodiya, Sanjay M. Vezzani, Annamaria Pharmacol Rev Review Articles Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with such drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life, so development of more effective therapies is an urgent clinical need. However, the various types of epilepsy and seizures and the complex temporal patterns of refractoriness complicate the issue. Furthermore, the underlying mechanisms of DRE are not fully understood, though recent work has begun to shape our understanding more clearly. Experimental models of DRE offer opportunities to discover, characterize, and challenge putative mechanisms of drug resistance. Furthermore, such preclinical models are important in developing therapies that may overcome drug resistance. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of ASD resistance and discuss how to overcome this problem. Encouragingly, better elucidation of the pathophysiological mechanisms underpinning epilepsies and drug resistance by concerted preclinical and clinical efforts have recently enabled a revised approach to the development of more promising therapies, including numerous potential etiology-specific drugs (“precision medicine”) for severe pediatric (monogenetic) epilepsies and novel multitargeted ASDs for acquired partial epilepsies, suggesting that the long hoped-for breakthrough in therapy for as-yet ASD-resistant patients is a feasible goal. SIGNIFICANCE STATEMENT: Drug resistance provides a major challenge in epilepsy management. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of drug resistance in epilepsy and discuss how the problem might be overcome. The American Society for Pharmacology and Experimental Therapeutics 2020-07 2020-07 /pmc/articles/PMC7300324/ /pubmed/32540959 http://dx.doi.org/10.1124/pr.120.019539 Text en Copyright © 2020 by The Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the CC BY-NC Attribution 4.0 International license (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Articles
Löscher, Wolfgang
Potschka, Heidrun
Sisodiya, Sanjay M.
Vezzani, Annamaria
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title_full Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title_fullStr Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title_full_unstemmed Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title_short Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
title_sort drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300324/
https://www.ncbi.nlm.nih.gov/pubmed/32540959
http://dx.doi.org/10.1124/pr.120.019539
work_keys_str_mv AT loscherwolfgang drugresistanceinepilepsyclinicalimpactpotentialmechanismsandnewinnovativetreatmentoptions
AT potschkaheidrun drugresistanceinepilepsyclinicalimpactpotentialmechanismsandnewinnovativetreatmentoptions
AT sisodiyasanjaym drugresistanceinepilepsyclinicalimpactpotentialmechanismsandnewinnovativetreatmentoptions
AT vezzaniannamaria drugresistanceinepilepsyclinicalimpactpotentialmechanismsandnewinnovativetreatmentoptions